HS-10383 / Jiangsu Hansoh Pharma - LARVOL DELTA

Safety, tolerability and pharmacokinetics of HS-10383 in healthy subjects: A randomized, double-blinded, placebo-controlled and multiple dose-ascending phase I trial (APSR 2024) - "This MAD phase I study demonstrated a favorable safety and PK profile of HS-10383."

Clinical • P1 data • PK/PD data • Chronic Cough • Cough • Respiratory Diseases

A Phase 2 Clinical Trial of HS-10383 in Chinese Adult Subjects With Refractory or Unexplained Chronic Cough (RUCC) (clinicaltrials.gov) - P2 | N=276 | Not yet recruiting | Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd.

New P2 trial • Chronic Cough • Cough • Pulmonary Disease • Respiratory Diseases

A First-In-Human study of HS-10383, a Selective P2X3 Receptor Antagonist for the treatment of Refractory or Unexplained Chronic Cough, in Healthy Chinese Subjects (APSR 2023) - No abstract available

Clinical • P1 data • Chronic Cough • Cough • Pulmonary Disease • Respiratory Diseases

A Multiple-Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetic of HS-10383 (clinicaltrials.gov) - P1 | N=48 | Recruiting | Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd.

New P1 trial • Cough • Respiratory Diseases

First-in-Human Study to Investigate the Safety and Tolerability and Pharmacokinetics of HS-10383 (clinicaltrials.gov) - P1 | N=32 | Recruiting | Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd.

New P1 trial • Cough • Respiratory Diseases